PHILADELPHIA, PA – May 7, 2018 – Lannett Company, Inc. (“Lannett”, NYSE: LCI) has announced the acquisition of 23 approved and one pending drug product applications from a subsidiary of Endo International plc (“Endo”, NasdaqGS: ENDP).

The purchase consideration consists of an undisclosed upfront payment and future milestone payments. The portfolio primarily includes oral solutions with a few semi-solid products that will be manufactured at Lannett’s liquid generics facility in Carmel, New York.

Bourne Partners, a Charlotte-based financial advisory firm focused exclusively in healthcare and life sciences, served as the sole financial advisor to Endo throughout the transaction.

About Endo International plc

Endo International plc (NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. For more information, visit www.endo.com.

About Lannett Company, Inc.

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.  For more information, visit www.lannett.com.